Treatment Response Imaging in Prostate Cancer

PET Clin. 2024 Apr 25:S1556-8598(24)00024-5. doi: 10.1016/j.cpet.2024.03.009. Online ahead of print.

Abstract

Objective criteria for measuring treatment response in prostate cancer are critical to clinical research and practice. The Prostate Cancer Working Group 3 criteria are widely accepted relying only on conventional imaging for radiographic treatment response. Prostate-specific membrane antigen PET/computed tomography was proven to be superior to conventional imaging in initial diagnosis and biochemical recurrence of prostate cancer. Moreover, there is growing evidence of its role in treatment response assessment in prostate cancer. This study will review the different criteria for imaging treatment response on conventional and advanced molecular imaging for different therapies, and the future perspective in posttherapy imaging.

Keywords: (177)Lu-PSMA; PSMA-PET; PSMA-SPECT; Prostate cancer; Treatment response.

Publication types

  • Review